Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-α, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis...Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-α, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.展开更多
Three children with severe atopic dermatitis were noted at routine follow- up to have developed multiple small pigmented macules during long- term therapy with topical tacrolimus 0.1% (Protopic., Fujisawa). Representa...Three children with severe atopic dermatitis were noted at routine follow- up to have developed multiple small pigmented macules during long- term therapy with topical tacrolimus 0.1% (Protopic., Fujisawa). Representative lesions in two of the three cases were confirmed histologically as simple lentigines. The focal distribution of lentigines to sites of tacrolimus use, and the temporal association between use of tacrolimus and development of lesions, suggest that topical tacrolimus is of direct aetiological relevance to their development. Careful long-term follow-up will be required to assess the clinical implications of these findings and whether they represent an increase in risk for melanocytic neoplasia.展开更多
文摘Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-α, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.
文摘Three children with severe atopic dermatitis were noted at routine follow- up to have developed multiple small pigmented macules during long- term therapy with topical tacrolimus 0.1% (Protopic., Fujisawa). Representative lesions in two of the three cases were confirmed histologically as simple lentigines. The focal distribution of lentigines to sites of tacrolimus use, and the temporal association between use of tacrolimus and development of lesions, suggest that topical tacrolimus is of direct aetiological relevance to their development. Careful long-term follow-up will be required to assess the clinical implications of these findings and whether they represent an increase in risk for melanocytic neoplasia.
